Clinical Trial Update: A Phase II Trial of Triapine (NSC #663249) in Combination With Gemcitabine as Second Line Treatment of Non-Small Cell Lung Cancer [Phase 2]

View source ↗

Summary

Phase II trial evaluating Triapine in combination with Gemcitabine as second-line treatment for recurrent non-small cell lung cancer has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Gemzar (gemcitabine)
• Triapine (Triapine)

Snippet

Sponsor: National Cancer Institute (NCI) | Conditions: Recurrent Non-small Cell Lung Cancer | Phase 2 | Status: COMPLETED